Cancer prevention agent development program: early phase clinical research - phase 0 trial of linaclotide to demonstrate colorectal bioactivity in healthy volunteers.
Ended Awarded Last action
- Contract number
- HHSN26100002
- Awardee
-
Mayo Clinic UEI T2NLSKHGK873
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $0
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value
- $0.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Rochester, MN 55905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$249,525 | |
| Other Administrative Action | $0 | |
| Original award | $249,525 |
Quick answers
Who was awarded contract HHSN26100002?
HHSN26100002 was awarded to Mayo Clinic by National Cancer Institute (National Institutes of Health) on September 24, 2012.
How much is contract HHSN26100002 worth?
The government has obligated $0 on HHSN26100002.
Is contract HHSN26100002 an order under another contract?
Yes. HHSN26100002 is a delivery order under HHSN261201200032I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100002 competed?
The extent of competition for HHSN26100002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award